By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its small molecule inhibitor HRS-6719. The drug will be tested as a monotherapy in patients with advanced solid tumors.
Mechanism of Action
HRS-6719 employs a synthetic lethality strategy, selectively targeting and inhibiting key biological processes in tumor cells, including mRNA splicing and DNA damage repair. This approach is designed to induce anti-tumor effects by exploiting vulnerabilities specific to cancer cells.
Global Innovation
No similar product has been approved globally, positioning HRS-6719 as a potential first-in-class therapy. This milestone underscores Hengrui’s commitment to developing innovative solutions for unmet medical needs in oncology.-Fineline Info & Tech